Altering Gut Microbiota May Be Beneficial Prior to MS Onset, But Not After, Mouse Study Indicates

Changing the gut’s microbial community (microbiota) with antibiotics prevented the development of multiple sclerosis (MS), but not its progression after the disease was established, data from a mouse model of the disease show. These findings support evidence that microbiota manipulations affect inflammatory immune responses involved in MS development, but…

Potential Therapy, Anavex 2-73, Shows Ability to Protect Neurons and Promote Myelin in Early Tests

Anavex Life Sciences‘ investigational therapy Anavex 2-73 (blarcamesine) showed an ability to protect, repair, and induce the formation of oligodendrocytes — the cells that produce the protective myelin layer around neurons — in early cell testing, researchers reported. These findings, which further establish the therapy’s potential as a treatment…

Top 10 Multiple Sclerosis Stories of 2019

Throughout 2019, Multiple Sclerosis News Today brought you daily coverage of the latest scientific findings, treatment developments, and clinical trials related to multiple sclerosis (MS). We look forward to reporting more news to patients, family members, and caregivers dealing with MS during 2020. Here are the top 10 most-read articles of…

MetP Pharma Awarded US Patent for Potential Remyelination Therapy

MetP Pharma‘s patent application for a new method to treat demyelinating and neuroinflammatory diseases, including multiple sclerosis (MS), has been approved by the United States Patent and Trademark Office (USPTO). The patent, titled “Treatment of Demyelinating Diseases” (U.S. Appl. No. 16/506,830), is valid until 2039,…